

**Dear colleagues  
and friends,**

Urology is a fascinating specialty and having the honour to organize the third biggest annual meeting in the western world, I would like to share our scientific achievements by offering a full-day academic program for two days in English language on the 27. and 28. Sept. 2012.



Reknown speakers of the European Society of Urology (EAU), the American Society (AUA), the International Society (SIU) and the International Continence Society (ICS) as well as from Eastern Europe countries will participate in the program of "Urology International" held for the first time in Leipzig, from 26 to 29 September 2012.

Leipzig is traditionally known as a centre for trade and exhibitions and played a key role during the "peaceful revolution" in autumn 1989, which was a decisive event for the reunification of Germany.

Besides "Urology International" there will be time enough to attend all other lectures and events in German language covering the wide spectrum of urology, such as andrology, urogynaecology, paediatric urology and renal transplantation.

With its modern and fascinating exhibition centre, Leipzig provides an ideal framework for our congress, while the pedestrian-friendly town centre invites people for a pleasant stroll through its traditional courtyards and arcades. The city represents the perfect mixture of intellectual, cultural and commercial life.

In addition for those who want to combine work and pleasure, very interesting cities like Dresden and Berlin are easily reachable by train and most of you know about our rich tradition and history there. I hope I could convince you to join us.

Welcome to Germany, welcome to Leipzig !

Prof. Dr. med. Dr. h.c. Stefan C. Müller

## The City of Leipzig

In 1497 Leipzig was granted the imperial trade fair privileges by Emperor Maximilian. Therefore Leipzig Fair is regarded the „mother of trade fairs“.

Leipzig's commercial development was given a boost in the 1990s due to the construction of the ultramodern Leipzig Fair Exhibition Centre with its fascinating architecture.

In the inner city, visitors can stroll through arcades and passageways reminiscent of former fair activities. Owing to its rich history in trade the city is still – or once again – an attractive location for investors like Porsche, BMW and DHL.



## 64. Kongress der Deutschen Gesellschaft für Urologie e.V. Leipzig, 26.–29. September 2012

### President

Prof. Dr. med. Dr. h.c. Stefan C. Müller  
Direktor der Klinik und Poliklinik  
für Urologie und Kinderurologie  
Universitätsklinikum Bonn  
Sigmund-Freud-Straße 25  
53105 Bonn  
Tel. +49 (0) 228 287 14286 | Fax +49 (0) 228 287 14285  
E-Mail: 2012@dgu.de

### Congress-Website

[www.dgu-kongress.de](http://www.dgu-kongress.de) (click on English)

# 64.

**Kongress der  
Deutschen Gesellschaft  
für Urologie e.V.**

26. – 29. September 2012  
Congress Center Leipzig

Präsident:  
Prof. Dr. med. Dr. h.c. Stefan C. Müller  
Direktor der Klinik u. Poliklinik für Urologie u. Kinderurologie  
Universitätsklinikum Bonn  
2012@dgu.de  
[www.dgu-kongress.de](http://www.dgu-kongress.de)

DGU goes  
International



Thursday, 27.09.2012

08:30 - 10:00

## Urology International

### Ureteral replacement, indications and techniques

Abol-Enein, H., Mansoura

### Preoperative decision making for nephron sparing surgery: Robotic vs open surgery

Esen, T., Istanbul

### Post-Traumatic Posterior Urethral Strictures: Pre operative Decision Making

Koraitim, M., Alexandria

### A contemporary update on the management of vesicovaginal fistula

Chapple, C.R., Sheffield

10:30 - 12:00

### Grand opening by DGU President

Mueller, S.C., Bonn

### Metabolic syndrome - abyss for health

Stumvoll, M., Leipzig

### Highlights of what's new in prostate cancer

Walsh, P.C., Baltimore-Maryland

13:00 - 14:30

## Urology International

### EAU Lecture: Is robotic becoming a standard for urologic surgery?

Abbou, C.-C.

### SIU Lecture: Urogynecology: What is proven in surgery for POP and SIU

Thüroff, J.W., Mainz

### AUA Lecture: Prostate Cancer Screening: Under standing the perspective of the US Preventive Services Task Force

Albertsen, P.C., Farmington

### ICS Lecture: The Overactive Bladder: A Critical Review

Schäfer, W., Pittsburgh

Thursday, 27.09.2012

14:30 - 16:00

## Urology International

### Urogynecology in 2012. Is it solely a gynecological or urological subspecialty or should it be a team work?

Majoros, A., Budapest

### Nephron-sparing surgery for the treatment of renal cell carcinoma of 4-7 cm in greatest dimension

Tchanturaia, Z., Tbilisi

### Oncogene up-regulation during androgen ablation in prostate cancer: a hurdle for endocrine therapy

Culig, Z., Innsbruck

### Current status in hypospadias surgery

Kröpfl, D., Essen

Friday, 28.09.2012

08:30-10:00

## Urology International: Epigenetics

- V15.1 Comparison of miRNA expression in primary tumors and distant metastases of clear cell renal cell carcinoma
- V15.2 MicroRNA expression profile in patients with renal cell cancer and tumor thrombus of the inferior vena cava
- V15.3 Microfluidic based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in sera of prostate cancer patients
- V15.4 The Biomarker miR-221 regulates STAT1 signaling in prostate cancer by targeting IRF2
- V15.5 Circulating microRNAs in serum: A novel biomarker for patients with bladder cancer?
- V15.6 Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic potential
- V15.7 Methylation of the methylated-DNA-protein-cysteine methyltransferase (MGMT) CpG island is an independent positive predictor for recurrence free survival of clear cell renal cell carcinoma patients
- V15.8 Histone Deacetylase Inhibitor (HDACi) LBH589 Rectifies Androgen receptor expression and its transcriptional activity in LNCaP and VCaP prostate cancer cells
- V15.9 Blocking HDAC abolishes resistance caused by chronic mTOR inhibition in prostate cancer cells

Friday, 28.09.2012

13:00-14:30

## Urology International: Bladder Cancer

- V18.1 Monitoring of intravesical BCG-instillation therapy of non-muscle invasive urothelial carcinoma through the detection of PPD (purified protein derivative) specific CD4 T cells
- V18.2 Thulium:YAG laser en bloc mucosectomy for staging and treatment of primary bladder cancer
- V18.3 Chemosensitization of bladder cancer cells by simultaneous siRNA-mediated inhibition of antiapoptotic Bcl-xL and survivin
- V18.4 External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial cancer of the bladder
- V18.5 Three differentiation states risk stratify bladder cancer into novel subtypes
- V18.6 Pathological Nodal Staging Scores for Bladder Cancer: A decision tool for adjuvant therapy after radical cystectomy
- V18.7 Circulating tumour cells are a powerful predictor of disease recurrence and survival after radical cystectomy in urothelial carcinoma of the bladder
- V18.8 Prediction of relapse- and progression-free survival in transitional cell carcinoma of the bladder using Bcl2 +21T>C polymorphism
- V18.9 Identification of prognostic factors for survival of patients with advanced or lymphatic metastatic Urothelial Carcroma and adjuvant Chemotherapy after radical Cystectomy

14:30-16:00

## Urology International: Prostate Cancer

- V24.1 Prevalence and prognostic significance of family history in 7135 patients with prostate cancer after radical prostatectomy
- V24.2 4.1B downregulation, but not EHM2 overexpression favours prostate cancer progression
- V24.3 Biochemical recurrence after radical prostatectomy: Does every patient with PSA 0.1ng/ml a relapse?
- V24.4 Objective histological grading of prostate cancer by fractal image analysis; can patients with Gleason score 7 be stratified by this approach?
- V24.5 Sex hormone-binding globulin is an independent predictor for biochemical recurrence after radical prostatectomy
- V24.6 Can sex hormone serum levels in addition to PSA improve prostate cancer prediction?
- V24.7 Coincidence of infrequent variants in ESCO1 and POLI are associated with TMPRSS2-ERG fusion and contribute to prostate cancer risk
- V24.8 Development and validation of an initial prostate biopsy pca3-based nomogram
- V24.9 Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi-institutional cohort